Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Pharmacoepidemiology | 18 | 2024 | 350 | 4.290 |
Why?
|
Research Design | 23 | 2024 | 6178 | 2.560 |
Why?
|
Databases, Factual | 18 | 2024 | 7956 | 2.080 |
Why?
|
Propensity Score | 12 | 2024 | 1908 | 1.950 |
Why?
|
Product Surveillance, Postmarketing | 4 | 2021 | 452 | 1.420 |
Why?
|
Data Mining | 7 | 2023 | 551 | 1.410 |
Why?
|
Advisory Committees | 4 | 2022 | 786 | 1.350 |
Why?
|
Warfarin | 7 | 2023 | 1483 | 1.220 |
Why?
|
Immunization Schedule | 2 | 2020 | 227 | 1.200 |
Why?
|
Anticoagulants | 11 | 2024 | 4813 | 1.150 |
Why?
|
Randomized Controlled Trials as Topic | 7 | 2024 | 10203 | 1.100 |
Why?
|
Delivery of Health Care | 10 | 2024 | 5335 | 1.050 |
Why?
|
Electronic Health Records | 12 | 2024 | 4811 | 0.980 |
Why?
|
Research Report | 3 | 2022 | 367 | 0.920 |
Why?
|
Factor XI | 1 | 2024 | 34 | 0.910 |
Why?
|
Scientific Misconduct | 1 | 2024 | 74 | 0.870 |
Why?
|
Bronchodilator Agents | 2 | 2024 | 512 | 0.870 |
Why?
|
Information Storage and Retrieval | 2 | 2019 | 819 | 0.860 |
Why?
|
Atrial Fibrillation | 9 | 2023 | 5127 | 0.850 |
Why?
|
Cross-Over Studies | 7 | 2021 | 2076 | 0.830 |
Why?
|
Adverse Drug Reaction Reporting Systems | 5 | 2023 | 488 | 0.760 |
Why?
|
Evidence-Based Medicine | 5 | 2024 | 3687 | 0.760 |
Why?
|
Haemophilus Vaccines | 1 | 2020 | 71 | 0.720 |
Why?
|
Diphtheria-Tetanus-acellular Pertussis Vaccines | 1 | 2020 | 38 | 0.700 |
Why?
|
Thromboembolism | 4 | 2024 | 996 | 0.690 |
Why?
|
Drug Evaluation | 1 | 2021 | 642 | 0.680 |
Why?
|
Neonatal Abstinence Syndrome | 1 | 2021 | 108 | 0.680 |
Why?
|
Rare Diseases | 1 | 2024 | 621 | 0.640 |
Why?
|
Medical Informatics Applications | 1 | 2021 | 178 | 0.640 |
Why?
|
Workflow | 1 | 2024 | 851 | 0.630 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 2 | 2024 | 3204 | 0.630 |
Why?
|
Valproic Acid | 1 | 2021 | 443 | 0.620 |
Why?
|
Abnormalities, Drug-Induced | 1 | 2021 | 339 | 0.610 |
Why?
|
Wet Macular Degeneration | 1 | 2020 | 162 | 0.600 |
Why?
|
Data Collection | 5 | 2022 | 3322 | 0.600 |
Why?
|
Diphtheria-Tetanus-Pertussis Vaccine | 1 | 2018 | 52 | 0.600 |
Why?
|
Drugs, Generic | 2 | 2020 | 448 | 0.590 |
Why?
|
Measles-Mumps-Rubella Vaccine | 1 | 2018 | 72 | 0.580 |
Why?
|
Technology | 1 | 2019 | 292 | 0.560 |
Why?
|
Choroidal Neovascularization | 1 | 2020 | 363 | 0.550 |
Why?
|
Pneumococcal Vaccines | 1 | 2020 | 397 | 0.550 |
Why?
|
Hemorrhage | 8 | 2023 | 3425 | 0.530 |
Why?
|
Natural Language Processing | 3 | 2019 | 1162 | 0.530 |
Why?
|
Calcium Channel Blockers | 1 | 2019 | 694 | 0.520 |
Why?
|
Peer Review | 1 | 2017 | 217 | 0.500 |
Why?
|
Drug Evaluation, Preclinical | 1 | 2020 | 1334 | 0.490 |
Why?
|
Epidemiologic Research Design | 2 | 2018 | 368 | 0.490 |
Why?
|
Reproducibility of Results | 12 | 2024 | 20093 | 0.490 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 2 | 2018 | 1517 | 0.480 |
Why?
|
Data Interpretation, Statistical | 6 | 2021 | 2691 | 0.470 |
Why?
|
Medical Records | 1 | 2019 | 1407 | 0.450 |
Why?
|
Software | 4 | 2024 | 4434 | 0.440 |
Why?
|
Humans | 86 | 2024 | 761423 | 0.420 |
Why?
|
Research | 2 | 2020 | 1977 | 0.420 |
Why?
|
Glaucoma, Open-Angle | 1 | 2019 | 738 | 0.410 |
Why?
|
Tetrazoles | 1 | 2018 | 909 | 0.410 |
Why?
|
Antihypertensive Agents | 2 | 2019 | 2023 | 0.400 |
Why?
|
Decision Making | 4 | 2020 | 3929 | 0.400 |
Why?
|
Androstadienes | 2 | 2024 | 348 | 0.390 |
Why?
|
Angiotensin Receptor Antagonists | 1 | 2018 | 1039 | 0.390 |
Why?
|
Drug Combinations | 3 | 2024 | 2048 | 0.390 |
Why?
|
Pneumonia | 1 | 2023 | 2140 | 0.380 |
Why?
|
Drug Approval | 1 | 2018 | 814 | 0.380 |
Why?
|
Control Groups | 1 | 2011 | 104 | 0.370 |
Why?
|
Heart Failure | 7 | 2024 | 11674 | 0.360 |
Why?
|
Administration, Inhalation | 2 | 2024 | 1156 | 0.350 |
Why?
|
Analgesics, Opioid | 3 | 2021 | 3804 | 0.330 |
Why?
|
Cohort Studies | 15 | 2024 | 41446 | 0.330 |
Why?
|
Longitudinal Studies | 3 | 2021 | 14599 | 0.320 |
Why?
|
Algorithms | 6 | 2024 | 14026 | 0.310 |
Why?
|
Models, Theoretical | 1 | 2020 | 3576 | 0.310 |
Why?
|
Case-Control Studies | 8 | 2021 | 22168 | 0.310 |
Why?
|
Seizures | 2 | 2018 | 2957 | 0.300 |
Why?
|
Medicare | 10 | 2023 | 6770 | 0.280 |
Why?
|
United States | 24 | 2023 | 72339 | 0.270 |
Why?
|
Stroke | 7 | 2023 | 9756 | 0.270 |
Why?
|
Vaccination | 2 | 2019 | 3381 | 0.270 |
Why?
|
Models, Statistical | 4 | 2024 | 5077 | 0.270 |
Why?
|
Drug Substitution | 2 | 2020 | 290 | 0.260 |
Why?
|
Guidelines as Topic | 4 | 2024 | 1385 | 0.260 |
Why?
|
Sentinel Surveillance | 2 | 2018 | 290 | 0.260 |
Why?
|
Disease Progression | 2 | 2020 | 13502 | 0.250 |
Why?
|
Medicaid | 4 | 2023 | 2818 | 0.240 |
Why?
|
Models, Biological | 2 | 2018 | 9469 | 0.240 |
Why?
|
Computer Simulation | 7 | 2024 | 6238 | 0.230 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2019 | 4014 | 0.230 |
Why?
|
Asthma | 1 | 2023 | 6211 | 0.230 |
Why?
|
Aged | 29 | 2024 | 169235 | 0.230 |
Why?
|
Influenza Vaccines | 2 | 2023 | 767 | 0.230 |
Why?
|
Brain Ischemia | 2 | 2018 | 3049 | 0.210 |
Why?
|
Famotidine | 1 | 2022 | 17 | 0.210 |
Why?
|
Antipsychotic Agents | 2 | 2014 | 3068 | 0.200 |
Why?
|
Diabetes Mellitus | 1 | 2020 | 5840 | 0.190 |
Why?
|
Time Factors | 11 | 2024 | 39975 | 0.190 |
Why?
|
Physicians | 1 | 2019 | 4591 | 0.190 |
Why?
|
Economics, Pharmaceutical | 2 | 2020 | 87 | 0.180 |
Why?
|
Terminology as Topic | 2 | 2019 | 1535 | 0.180 |
Why?
|
Teratogens | 1 | 2021 | 117 | 0.180 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2019 | 5302 | 0.180 |
Why?
|
Spironolactone | 1 | 2024 | 412 | 0.180 |
Why?
|
Prognosis | 4 | 2024 | 29620 | 0.170 |
Why?
|
Drug Monitoring | 2 | 2018 | 962 | 0.170 |
Why?
|
Embolism | 1 | 2023 | 400 | 0.170 |
Why?
|
Bacterial Capsules | 1 | 2020 | 244 | 0.170 |
Why?
|
Utah | 1 | 2019 | 131 | 0.170 |
Why?
|
Aged, 80 and over | 12 | 2020 | 58956 | 0.160 |
Why?
|
Particulate Matter | 1 | 2011 | 2595 | 0.160 |
Why?
|
Adrenergic Antagonists | 1 | 2018 | 26 | 0.160 |
Why?
|
Risk Assessment | 8 | 2024 | 23990 | 0.150 |
Why?
|
Drug Repositioning | 1 | 2020 | 233 | 0.150 |
Why?
|
Insurance Claim Review | 2 | 2020 | 741 | 0.150 |
Why?
|
Sulfonylurea Compounds | 1 | 2019 | 219 | 0.150 |
Why?
|
Glipizide | 1 | 2017 | 48 | 0.150 |
Why?
|
Hypoglycemic Agents | 3 | 2021 | 3081 | 0.150 |
Why?
|
Clindamycin | 1 | 2018 | 139 | 0.150 |
Why?
|
Perioperative Care | 2 | 2015 | 1033 | 0.150 |
Why?
|
Checklist | 1 | 2024 | 828 | 0.140 |
Why?
|
Validation Studies as Topic | 1 | 2017 | 162 | 0.140 |
Why?
|
Hospitalization | 6 | 2024 | 10718 | 0.140 |
Why?
|
Air Pollution | 1 | 2011 | 2348 | 0.140 |
Why?
|
Female | 25 | 2024 | 392581 | 0.140 |
Why?
|
Glyburide | 1 | 2017 | 116 | 0.140 |
Why?
|
Stroke Volume | 3 | 2024 | 5497 | 0.140 |
Why?
|
Prescription Drugs | 2 | 2014 | 631 | 0.140 |
Why?
|
Male | 25 | 2024 | 360736 | 0.140 |
Why?
|
Angioedema | 1 | 2018 | 191 | 0.140 |
Why?
|
Vitamin K | 2 | 2020 | 318 | 0.140 |
Why?
|
Environmental Exposure | 1 | 2011 | 4467 | 0.130 |
Why?
|
Information Dissemination | 1 | 2024 | 1126 | 0.130 |
Why?
|
Treatment Outcome | 9 | 2024 | 64651 | 0.130 |
Why?
|
Monte Carlo Method | 2 | 2019 | 1257 | 0.130 |
Why?
|
Trust | 1 | 2020 | 530 | 0.130 |
Why?
|
Dipeptidyl-Peptidase IV Inhibitors | 1 | 2019 | 311 | 0.120 |
Why?
|
Antithrombins | 1 | 2018 | 294 | 0.120 |
Why?
|
Statistics as Topic | 2 | 2018 | 2358 | 0.120 |
Why?
|
Proportional Hazards Models | 4 | 2020 | 12456 | 0.120 |
Why?
|
Logistic Models | 6 | 2020 | 13255 | 0.120 |
Why?
|
Odds Ratio | 4 | 2020 | 9645 | 0.120 |
Why?
|
Ketolides | 1 | 2014 | 12 | 0.120 |
Why?
|
Risk | 2 | 2020 | 9612 | 0.120 |
Why?
|
Lung Neoplasms | 1 | 2019 | 13337 | 0.120 |
Why?
|
Evidence-Based Practice | 1 | 2018 | 495 | 0.110 |
Why?
|
Biphenyl Compounds | 1 | 2018 | 1007 | 0.110 |
Why?
|
Postoperative Period | 1 | 2018 | 1815 | 0.110 |
Why?
|
United States Food and Drug Administration | 2 | 2018 | 1664 | 0.110 |
Why?
|
Isoxazoles | 1 | 2014 | 231 | 0.100 |
Why?
|
International Normalized Ratio | 1 | 2014 | 382 | 0.100 |
Why?
|
Cyclooxygenase 2 Inhibitors | 1 | 2014 | 321 | 0.100 |
Why?
|
Marketing | 1 | 2014 | 220 | 0.100 |
Why?
|
Comparative Effectiveness Research | 1 | 2017 | 709 | 0.100 |
Why?
|
Middle Aged | 14 | 2024 | 220826 | 0.100 |
Why?
|
Pennsylvania | 1 | 2013 | 613 | 0.100 |
Why?
|
Metformin | 1 | 2019 | 906 | 0.100 |
Why?
|
Automation | 1 | 2014 | 586 | 0.100 |
Why?
|
Secondary Prevention | 1 | 2018 | 1474 | 0.100 |
Why?
|
Adult | 12 | 2024 | 221148 | 0.090 |
Why?
|
Mathematical Computing | 1 | 2011 | 142 | 0.090 |
Why?
|
Diabetes Mellitus, Type 2 | 3 | 2021 | 12143 | 0.090 |
Why?
|
Clostridium Infections | 1 | 2018 | 558 | 0.090 |
Why?
|
Quinolones | 1 | 2014 | 378 | 0.090 |
Why?
|
Medical Oncology | 1 | 2022 | 2321 | 0.090 |
Why?
|
Chemoprevention | 1 | 2013 | 326 | 0.090 |
Why?
|
Registries | 2 | 2024 | 8223 | 0.090 |
Why?
|
Pregnancy Outcome | 1 | 2021 | 2920 | 0.090 |
Why?
|
Hypoglycemia | 1 | 2017 | 884 | 0.090 |
Why?
|
Primary Prevention | 1 | 2018 | 1186 | 0.090 |
Why?
|
Age Factors | 3 | 2018 | 18400 | 0.080 |
Why?
|
Adrenergic beta-Antagonists | 1 | 2015 | 1241 | 0.080 |
Why?
|
Decision Support Techniques | 1 | 2019 | 1998 | 0.080 |
Why?
|
Drug Utilization | 1 | 2015 | 1188 | 0.080 |
Why?
|
Kaplan-Meier Estimate | 1 | 2019 | 6479 | 0.080 |
Why?
|
Incidence | 5 | 2019 | 21341 | 0.080 |
Why?
|
Disease-Free Survival | 1 | 2019 | 6814 | 0.080 |
Why?
|
Clinical Trials as Topic | 1 | 2024 | 8000 | 0.080 |
Why?
|
Drug Therapy, Combination | 1 | 2018 | 6309 | 0.080 |
Why?
|
Epidemiologic Methods | 1 | 2013 | 1336 | 0.080 |
Why?
|
Influenza, Human | 1 | 2019 | 1521 | 0.070 |
Why?
|
Anti-Bacterial Agents | 2 | 2018 | 7409 | 0.070 |
Why?
|
Risk Factors | 8 | 2023 | 74167 | 0.070 |
Why?
|
Infant | 2 | 2020 | 36205 | 0.070 |
Why?
|
Antidepressive Agents | 1 | 2019 | 2897 | 0.070 |
Why?
|
United States Department of Veterans Affairs | 1 | 2011 | 928 | 0.070 |
Why?
|
Patient Selection | 1 | 2018 | 4244 | 0.070 |
Why?
|
Survival Analysis | 1 | 2019 | 10089 | 0.070 |
Why?
|
Ventricular Function, Left | 1 | 2018 | 3879 | 0.060 |
Why?
|
Recurrence | 1 | 2018 | 8469 | 0.060 |
Why?
|
Sulfonamides | 1 | 2014 | 1975 | 0.060 |
Why?
|
Denmark | 2 | 2018 | 771 | 0.060 |
Why?
|
Piperazines | 1 | 2014 | 2523 | 0.060 |
Why?
|
Adolescent | 6 | 2022 | 88313 | 0.050 |
Why?
|
Child, Preschool | 3 | 2020 | 42254 | 0.050 |
Why?
|
Omeprazole | 1 | 2022 | 105 | 0.050 |
Why?
|
Calibration | 1 | 2024 | 818 | 0.050 |
Why?
|
Cardiovascular Diseases | 3 | 2015 | 15498 | 0.050 |
Why?
|
Epilepsy | 1 | 2016 | 3290 | 0.050 |
Why?
|
Infant, Newborn | 1 | 2021 | 26212 | 0.050 |
Why?
|
Retrospective Studies | 5 | 2022 | 80582 | 0.050 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2015 | 3244 | 0.040 |
Why?
|
Pregnancy | 1 | 2021 | 29862 | 0.040 |
Why?
|
Reference Standards | 1 | 2022 | 1004 | 0.040 |
Why?
|
Vaccines, Inactivated | 1 | 2019 | 179 | 0.040 |
Why?
|
Taiwan | 1 | 2019 | 516 | 0.040 |
Why?
|
Orthomyxoviridae | 1 | 2019 | 149 | 0.040 |
Why?
|
Veterans | 1 | 2011 | 2647 | 0.040 |
Why?
|
Causality | 1 | 2024 | 1243 | 0.040 |
Why?
|
Research Personnel | 1 | 2022 | 588 | 0.040 |
Why?
|
Proton Pump Inhibitors | 1 | 2022 | 531 | 0.040 |
Why?
|
Child | 3 | 2020 | 80162 | 0.040 |
Why?
|
Medical Record Linkage | 1 | 2018 | 285 | 0.040 |
Why?
|
Respiratory Syncytial Virus, Human | 1 | 2019 | 150 | 0.030 |
Why?
|
Societies, Scientific | 1 | 2017 | 222 | 0.030 |
Why?
|
Emergency Service, Hospital | 2 | 2017 | 7874 | 0.030 |
Why?
|
Community Health Planning | 1 | 2016 | 164 | 0.030 |
Why?
|
Insurance, Health | 2 | 2018 | 2497 | 0.030 |
Why?
|
Phenprocoumon | 1 | 2014 | 20 | 0.030 |
Why?
|
Codeine | 1 | 2014 | 51 | 0.030 |
Why?
|
Tramadol | 1 | 2014 | 60 | 0.030 |
Why?
|
Program Development | 1 | 2020 | 1298 | 0.030 |
Why?
|
Young Adult | 5 | 2019 | 59207 | 0.030 |
Why?
|
Severity of Illness Index | 2 | 2024 | 15838 | 0.030 |
Why?
|
International Classification of Diseases | 1 | 2018 | 909 | 0.030 |
Why?
|
Postoperative Complications | 1 | 2015 | 15650 | 0.030 |
Why?
|
Consensus | 1 | 2022 | 3122 | 0.030 |
Why?
|
Insurance Coverage | 1 | 2023 | 1940 | 0.020 |
Why?
|
Internationality | 1 | 2017 | 1001 | 0.020 |
Why?
|
Massachusetts | 1 | 2024 | 8832 | 0.020 |
Why?
|
Administration, Oral | 1 | 2019 | 4016 | 0.020 |
Why?
|
Age Distribution | 1 | 2016 | 2880 | 0.020 |
Why?
|
Bayes Theorem | 1 | 2018 | 2328 | 0.020 |
Why?
|
Drug Interactions | 1 | 2014 | 1414 | 0.020 |
Why?
|
Prospective Studies | 3 | 2020 | 54415 | 0.020 |
Why?
|
Academic Medical Centers | 1 | 2018 | 2760 | 0.020 |
Why?
|
Drug Administration Schedule | 1 | 2015 | 4852 | 0.020 |
Why?
|
Anticonvulsants | 1 | 2016 | 1906 | 0.020 |
Why?
|
Comorbidity | 1 | 2020 | 10498 | 0.020 |
Why?
|
Predictive Value of Tests | 1 | 2018 | 15262 | 0.010 |
Why?
|
Sex Factors | 1 | 2014 | 10548 | 0.010 |
Why?
|
Follow-Up Studies | 1 | 2015 | 39117 | 0.010 |
Why?
|